California Life Sciences Association (CLSA) welcomes the introduction of H.R. 4617, legislation that places a 5-year freeze on the ill-conceived 2.3% medical device excise tax. Without swift enactment of this measure, the medical device tax would further hamper innovation and investment in medical technology research and development.
See the highlights from our 2018 California Life Sciences Industry Report and learn how the Golden State leads the world in life sciences innovation, educating thousands of new scientists, attracting billions in public and private investment, employing thousands and producing hundreds of new therapies and technologies to improve patient care.
CLSA was recently featured in BioWorld, regarding the growth of California’s life sciences industry.
CLSA was recently featured in BioPharmaDive regarding the growth of California’s life sciences industry in contrast with the Massachusetts bioscience cluster.
More than 3 million Americans suffer from Inflammatory Bowel Disease (IBD), an umbrella term for two distinct conditions – Crohn’s disease and ulcerative colitis. Download CLSA’s latest report to learn more about this disease, view patient stories, and learn how public policies can improve patient access to IBD therapies.
CLSA was recently featured in the San Diego Union-Tribune, discussing the growth of the San Diego County life sciences innovation ecosystem.
In 2011, the City of South San Francisco approved a redevelopment plan for the Oyster Point area. The Oyster Point Specific Plan called for 81 acres east of Highway 101 to be developed with new life sciences companies, upgrades to the marina and a potential hotel.
Congress is currently advancing legislation in both chambers to significantly overhaul the U.S. tax code. Historically, CLSA has focused our tax-related advocacy efforts around: (1) calling for an update and making permanent of the R&D Tax Credit, (2) protecting the Orphan Drug Tax Credit (ODTC), and (3) opposing the creation of and later calling for a repeal of the medical device tax.
The Independent Payment Advisory Board (IPAB) is a controversial advisory board enacted as part of the Affordable Care Act in 2010, which threatens seniors’ care and could harm biomedical innovation by reducing incentives for investment in new research and product development.
CLSA was recently featured in the San Francisco Chronicle, outlining life sciences industry concerns with a proposed housing development at Oyster Point in South San Francisco.